These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

466 related articles for article (PubMed ID: 29900553)

  • 1. Change in the hepatic profile of hepatitis C virus genotype 4-infected patients with compensated cirrhosis receiving ombitasvir, paritaprevir, and ritonavir plus ribavirin: A subanalysis of the AGATE-II study.
    Waked I; Esmat G; Fouad R; Allam N; Hassany M; Mohey M; Shiha G; Soliman R; Qaqish RB; Hall C; Alami NN; Kopecky-Bromberg S; Mobashery N
    J Med Virol; 2018 Nov; 90(11):1739-1744. PubMed ID: 29900553
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ombitasvir, paritaprevir, and ritonavir plus ribavirin for chronic hepatitis C virus genotype 4 infection in Egyptian patients with or without compensated cirrhosis (AGATE-II): a multicentre, phase 3, partly randomised open-label trial.
    Waked I; Shiha G; Qaqish RB; Esmat G; Yosry A; Hassany M; Soliman R; Mohey MA; Allam N; Zayed N; Asselah T; Hall C; Redman R; Mobashery N; Doss W
    Lancet Gastroenterol Hepatol; 2016 Sep; 1(1):36-44. PubMed ID: 28404110
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ombitasvir, paritaprevir, and ritonavir plus ribavirin in adults with hepatitis C virus genotype 4 infection and cirrhosis (AGATE-I): a multicentre, phase 3, randomised open-label trial.
    Asselah T; Hézode C; Qaqish RB; ElKhashab M; Hassanein T; Papatheodoridis G; Feld JJ; Moreno C; Zeuzem S; Ferenci P; Yu Y; Redman R; Pilot-Matias T; Mobashery N
    Lancet Gastroenterol Hepatol; 2016 Sep; 1(1):25-35. PubMed ID: 28404108
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world safety and efficacy of paritaprevir/ritonavir/ombitasvir plus dasabuvir ± ribavirin in patients with hepatitis C virus genotype 1 and advanced hepatic fibrosis or compensated cirrhosis: a multicenter pooled analysis.
    Chen CH; Chen CH; Lin CL; Lin CY; Hu TH; Tung SY; Hsieh SY; Lu SN; Chien RN; Hung CH; Sheen IS
    Sci Rep; 2019 May; 9(1):7086. PubMed ID: 31068655
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ombitasvir/paritaprevir/ritonavir+dasabuvir+ribavirin for chronic hepatitis C virus genotype 1b-infected cirrhotics (TURQUOISE-IV).
    Isakov V; Paduta D; Viani RM; Enejosa JV; Pasechnikov V; Znoyko O; Ogurtsov P; Bogomolov PO; Maevskaya MV; Chen X; Shulman NS
    Eur J Gastroenterol Hepatol; 2018 Sep; 30(9):1073-1076. PubMed ID: 29762255
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ombitasvir/Paritaprevir/Ritonavir: A Review in Chronic HCV Genotype 4 Infection.
    Keating GM
    Drugs; 2016 Aug; 76(12):1203-11. PubMed ID: 27401997
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial.
    Hézode C; Asselah T; Reddy KR; Hassanein T; Berenguer M; Fleischer-Stepniewska K; Marcellin P; Hall C; Schnell G; Pilot-Matias T; Mobashery N; Redman R; Vilchez RA; Pol S
    Lancet; 2015 Jun; 385(9986):2502-9. PubMed ID: 25837829
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and Safety of Ombitasvir, Paritaprevir, and Ritonavir in an Open-Label Study of Patients With Genotype 1b Chronic Hepatitis C Virus Infection With and Without Cirrhosis.
    Lawitz E; Makara M; Akarca US; Thuluvath PJ; Preotescu LL; Varunok P; Morillas RM; Hall C; Mobashery N; Redman R; Pilot-Matias T; Vilchez RA; Hézode C
    Gastroenterology; 2015 Oct; 149(4):971-80.e1. PubMed ID: 26170136
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study.
    Petta S; Marzioni M; Russo P; Aghemo A; Alberti A; Ascione A; Antinori A; Bruno R; Bruno S; Chirianni A; Gaeta GB; Giannini EG; Merli M; Messina V; Montilla S; Perno CF; Puoti M; Raimondo G; Rendina M; Silberstein FC; Villa E; Zignego AL; Pani L; Craxì A; ;
    Lancet Gastroenterol Hepatol; 2017 Jun; 2(6):427-434. PubMed ID: 28497758
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized Phase 3 Trial of Ombitasvir/Paritaprevir/Ritonavir and Ribavirin for Hepatitis C Virus Genotype 2-Infected Japanese Patients.
    Sato K; Chayama K; Alves K; Toyoda H; Suzuki F; Kato K; Rodrigues L; Zhang X; Setze C; Pilot-Matias T; Burroughs M; Redman R; Kumada H
    Adv Ther; 2017 Jun; 34(6):1449-1465. PubMed ID: 28536999
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Paritaprevir/ritonavir/ombitasvir and dasabuvir for the treatment of chronic hepatitis C virus infection.
    Cheng EY; Saab S; Holt CD; Busuttil RW
    Expert Opin Pharmacother; 2015; 16(18):2835-48. PubMed ID: 26646975
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ombitasvir/paritaprevir/ritonavir and dasabuvir tablets for hepatitis C virus genotype 1 infection.
    Klibanov OM; Gale SE; Santevecchi B
    Ann Pharmacother; 2015 May; 49(5):566-81. PubMed ID: 25680759
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Paritaprevir/ritonavir/ombitasvir plus dasabuvir with ribavirin for treatment of recurrent chronic hepatitis C genotype 1 infection after liver transplantation: Real-world experience.
    Yu ML; Chen YL; Huang CF; Lin KH; Yeh ML; Huang CI; Hsieh MH; Lin ZY; Chen SC; Huang JF; Dai CY; Chuang WL
    J Formos Med Assoc; 2018 Jun; 117(6):518-526. PubMed ID: 28662883
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sustained virologic response of 100% in HCV genotype 1b patients with cirrhosis receiving ombitasvir/paritaprevir/r and dasabuvir for 12weeks.
    Feld JJ; Moreno C; Trinh R; Tam E; Bourgeois S; Horsmans Y; Elkhashab M; Bernstein DE; Younes Z; Reindollar RW; Larsen L; Fu B; Howieson K; Polepally AR; Pangerl A; Shulman NS; Poordad F
    J Hepatol; 2016 Feb; 64(2):301-307. PubMed ID: 26476290
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Real-world Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir for Hepatitis C Genotype 1.
    Miyasaka A; Yoshida Y; Yoshida T; Murakami A; Abe K; Ohuchi K; Kawakami T; Watanabe D; Hoshino T; Sawara K; Takikawa Y
    Intern Med; 2018 Oct; 57(19):2807-2812. PubMed ID: 29780135
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ombitasvir/paritaprevir/r, dasabuvir and ribavirin for cirrhotic HCV patients with thrombocytopaenia and hypoalbuminaemia.
    Forns X; Poordad F; Pedrosa M; Berenguer M; Wedemeyer H; Ferenci P; Shiffman ML; Fried MW; Lovell S; Trinh R; Lopez-Talavera JC; Everson G
    Liver Int; 2015 Nov; 35(11):2358-62. PubMed ID: 26248955
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High success rates for the use of ombitasvir/paritaprevir/ritonavir containing regimens in treatment of naïve and experienced chronic hepatitis C genotype 4: Real world results.
    El Kassas M; Alboraie M; Omar H; El Latif YA; Algaber MA; El Tahan A; El Halwagy H; Afify S; Elserafy M; Elsaeed K; Doss W
    J Med Virol; 2022 Feb; 94(2):667-674. PubMed ID: 30950069
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ombitasvir, paritaprevir, and ritonavir plus dasabuvir for 8 weeks in previously untreated patients with hepatitis C virus genotype 1b infection without cirrhosis (GARNET): a single-arm, open-label, phase 3b trial.
    Welzel TM; Asselah T; Dumas EO; Zeuzem S; Shaw D; Hazzan R; Forns X; Pilot-Matias T; Lu W; Cohen DE; Feld JJ
    Lancet Gastroenterol Hepatol; 2017 Jul; 2(7):494-500. PubMed ID: 28416221
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 12 weeks ombitasvir/paritaprevir-ritonavir + ribavirin achieve high SVR rates in HCV-4 patients with advanced fibrosis.
    Degasperi E; Aghemo A; Paolucci S; D'Ambrosio R; Borghi M; Perbellini R; Novazzi F; De Nicola S; Lunghi G; Baldanti F; Lampertico P
    Dig Liver Dis; 2018 Jul; 50(7):703-706. PubMed ID: 29499903
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis.
    Poordad F; Hezode C; Trinh R; Kowdley KV; Zeuzem S; Agarwal K; Shiffman ML; Wedemeyer H; Berg T; Yoshida EM; Forns X; Lovell SS; Da Silva-Tillmann B; Collins CA; Campbell AL; Podsadecki T; Bernstein B
    N Engl J Med; 2014 May; 370(21):1973-82. PubMed ID: 24725237
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.